Novartis Receives EU Clearance for JETREA

Alcon, the Fort Worth, Texas-based eye care division of healthcare products company Novartis, has announced that it has received European clearance for JETREA.

Advertisement
Carrie Pallardy

Alcon received the rights to market JETREA, an injectable treatment of vitreomacular traction, in the US in October 2012.

More Articles on Ophthalmology:
EyeTechCare Receives $13M in Funding
10 Statistics on Ophthalmologist Compensation by Location
Flaum Eye Institute Recruits Dr. Harold Ross

How health plans can close the execution gap in value-based care — A practical AI-driven approach

Recommended Live Webinar on Mar 31, 2026 11:00 AM - 12:00 PM CST

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.